Skip to main content
Michael Schwarzschild, MD, Neurology, Boston, MA, Massachusetts General Hospital

MichaelASchwarzschildMDPhD

Neurology • Boston, MA

Professor of Neurology, Harvard Medical School; Associate in Neurology,Massachusetts General Hospital.

Join to view full profile

Dr. Schwarzschild is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Schwarzschild's full profile

Already have an account?

  • Office

    15 Parkman St
    Wac 835 Neurology Associates
    Boston, MA 02114
    Phone+1 617-726-5532
    Fax+1 617-724-1480
  • Is this information wrong?

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical School
    Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1991 - 1994
  • Brigham and Women's Hospital
    Brigham and Women's HospitalInternship, Internal Medicine, 1990 - 1991
  • Harvard Medical School
    Harvard Medical SchoolClass of 1990

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1994 - 2025
  • PA State Medical License
    PA State Medical License 2001 - 2009
  • American Board of Psychiatry and Neurology Neurology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Efficacy of Nilotinib in Patients with Moderately Advanced Parkinson Disease  
    Michael Schwarzschild, MD, JAMA Neurology

Press Mentions

  • Antioxidant Fails to Slow Parkinson’s Disease Progression in Clinical Trial
    Antioxidant Fails to Slow Parkinson’s Disease Progression in Clinical TrialSeptember 16th, 2021
  • Antioxidant Therapy Tested in Early Parkinson’s
    Antioxidant Therapy Tested in Early Parkinson’sSeptember 14th, 2021
  • NSAIDs Reduce LRRK2 Penetrance in Parkinson's Disease
    NSAIDs Reduce LRRK2 Penetrance in Parkinson's DiseaseSeptember 3rd, 2020
  • Join now to see all

Grant Support

  • Pursuing Purine Pathways To Clinical Trials For Parkinson'S DiseaseNational Institute Of Neurological Disorders And Stroke2009–2012
  • Uric Acid:Novel Therapeutic Target For Parkinson'S DiseaseNational Institute Of Neurological Disorders And Stroke2009–2010
  • Translational Foundation Of Adenosine Antagonist Use For DyskinesiasNational Institute Of Neurological Disorders And Stroke2006–2010
  • Pursuing Purinergic Pathways To Clinical Trials For Parkinson'S DiseaseNational Institute Of Neurological Disorders And Stroke2008
  • Targeting Adenosine A2A Receptors In Parkinson'S DiseaseNational Institute Of Neurological Disorders And Stroke2006
  • Assess The Efficacy &Safety Of CEP-1347 In PTS W/Early Parkinson'S DiseaseNational Center For Research Resources2004–2006
  • A2A Adenosine Receptors In Psychostimulant SensitizationNational Institute On Drug Abuse2001–2005
  • Novel Neuroprotection By Caffeine In Parkinson'S DiseaseNational Institute Of Environmental Health Sciences2001–2005
  • Translating A2A Receptor Biology Into Novel PD TherapyNational Institute Of Neurological Disorders And Stroke2002
  • A2A Adenosine Receptor--A Novel Role In NeuroprotectionNational Institute On Aging2000
  • Adenosine A2 Receptors And Psychostimulant InteractionsNational Institute On Drug Abuse1996–1999
  • RAS And Neuronal Gene Regulation By CNTFNational Institute Of Neurological Disorders And Stroke1994–1998

Professional Memberships

Hospital Affiliations

Dr. Michael Schwarzschild, Dr. Michael Schwarzschild, MD, Dr. M Schwarzschild, Dr. Michael A Schwarzschild